Literature DB >> 11254095

Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins.

I Van Overbeke1, K Chiers, R Ducatelle, F Haesebrouck.   

Abstract

The efficacy of a subunit vaccine containing the Apx toxins of Actinobacillus pleuropneumoniae and transferrin-binding proteins was determined. Ten pigs were vaccinated twice with the vaccine. Eight control animals were injected twice with a saline solution. Three weeks after the second vaccination, all pigs were endobronchially inoculated with 10(6.5) colony-forming units (CFU) of an A. pleuropneumoniae serotype 9 strain. In the vaccine group, none of the pigs died after inoculation. Only one pig of the control group survived challenge. Surviving pigs were killed at 7 days after challenge. The mean percentage of affected lung tissue was 64% in the control group and 17% in the vaccine group. Actinobacillus pleuropneumoniae was isolated from the lungs of all animals. The mean bacterial titres of the caudal lung lobes were 5.0 x 10(8) CFU/g in the control group and 3.0 x 10(6) CFU/g in the vaccine group. It was concluded that the vaccine induced partial protection against severe challenge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254095     DOI: 10.1046/j.1439-0450.2001.00419.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  9 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Field experience with two different vaccination strategies aiming to control infections with Actinobacillus pleuropneumoniae in a fattening pig herd.

Authors:  Marie Sjölund; Per Wallgren
Journal:  Acta Vet Scand       Date:  2010-03-25       Impact factor: 1.695

3.  Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.

Authors:  Lenka Sadilkova; Jiri Nepereny; Vladimir Vrzal; Peter Sebo; Radim Osicka
Journal:  Vet Res       Date:  2012-01-12       Impact factor: 3.683

4.  In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.

Authors:  Fabio Antenucci; Cyrielle Fougeroux; Alannah Deeney; Cathrine Ørskov; Andrew Rycroft; Peter Johannes Holst; Anders Miki Bojesen
Journal:  Vet Res       Date:  2018-01-09       Impact factor: 3.683

5.  Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae.

Authors:  Fabio Antenucci; Cyrielle Fougeroux; Janine T Bossé; Zofia Magnowska; Camille Roesch; Paul Langford; Peter Johannes Holst; Anders Miki Bojesen
Journal:  Vet Res       Date:  2017-11-09       Impact factor: 3.683

Review 6.  Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Authors:  Virginia Aida; Vasilis C Pliasas; Peter J Neasham; J Fletcher North; Kirklin L McWhorter; Sheniqua R Glover; Constantinos S Kyriakis
Journal:  Front Vet Sci       Date:  2021-04-15

7.  Microarray-based comparative genomic profiling of reference strains and selected Canadian field isolates of Actinobacillus pleuropneumoniae.

Authors:  Julien Gouré; Wendy A Findlay; Vincent Deslandes; Anne Bouevitch; Simon J Foote; Janet I MacInnes; James W Coulton; John H E Nash; Mario Jacques
Journal:  BMC Genomics       Date:  2009-02-24       Impact factor: 3.969

8.  Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE.

Authors:  Tamás Hatfaludi; Keith Al-Hasani; Lan Gong; John D Boyce; Mark Ford; Ian W Wilkie; Noelene Quinsey; Michelle A Dunstone; David E Hoke; Ben Adler
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 9.  Antibiotic Resistance in the Food Chain: A Developing Country-Perspective.

Authors:  Luria Leslie Founou; Raspail Carrel Founou; Sabiha Yusuf Essack
Journal:  Front Microbiol       Date:  2016-11-23       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.